Navigation Links
MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results
Date:3/13/2008

otential partners for the rest of world (territories outside North America and Europe) rights held by MIGENIX although the timing and completion of such a partnership(s) is uncertain at this time.

Celgosivir (MX-3253; oral alpha-glucosidase I inhibitor; treatment of chronic hepatitis C virus infections): A Phase II study is currently enrolling patients to assess 600 mg celgosivir for tolerability, pharmacokinetics and viral kinetics when combined with the standard of care drugs, pegylated interferon alfa-2b plus ribavirin, as compared to the standard of care drugs alone and to 400 mg celgosivir plus the standard of care for up to 12 weeks of therapy. With 15 patients enrolled to date, it is planned that approximately six additional patients will be enrolled. In February, one of the two contract research organizations we were using to conduct this study shut down operations unexpectedly. We are in the process of transferring the planned operations at this site including patients that have been qualified for enrollment to another clinical site, and obtaining the required Institutional Review Board approval for this site. We maintain our expectation for results from the study in the third calendar quarter of 2008. MIGENIX has been and continues to be in discussions with potential partners for the further clinical development of celgosivir although the timing and completion of a partnership is uncertain at this time.

Omiganan (CLS001; topical cationic peptide; treatment of dermatological diseases): Based on positive results from a recently completed Phase II clinical study for the treatment of rosacea, our partner in this program, Cutanea Life Sciences intends to enter Phase III clinical development later this calendar year.

MX-2401 (IV lipopeptide; treatment of gram-positive bacterial infections): MX-2401 is an injectable lipopeptide being developed for the treatment of serious gram positive bacterial infections. To date, preclinical studies conduc
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. MIGENIX Third Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
2. MIGENIX releases CEO message #22
3. MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
4. MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results
5. MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
6. MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
7. MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
8. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
9. MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
10. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
11. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... In recent years, growing suspicion about the ... development and promotion has led to unprecedented levels of ... concerns about the insidious impact of commercialization of research, ... to the world’s biggest pharmas for illegal marketing activities, ...
(Date:1/14/2014)... , Jan. 14, 2014   Kinaxis ®, provider of ... and sales and operations planning ( S&OP ) service, is ... Summit , which will be held at the Hilton San ... join Kinaxis customer Elisabeth Kaszas , Director of Supply ...
(Date:1/14/2014)... Rochester, NY (PRWEB) January 14, 2014 During ... is now known as “The Doctor’s Plague.” In this time ... their hands. This led, at times, to the death of ... staff today don’t know that they may be unwittingly transmitting ...
(Date:1/14/2014)... 14, 2014 Holloway America today announced ... material test reports (MTRs) for all pressure vessels and ... results is particularly important for equipment that must meet ... Library features search functionality that allows authorized users to ...
Breaking Biology Technology:The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3Pressure Vessel Design and Fabrication Company Builds Database for Material Test Reports 2Pressure Vessel Design and Fabrication Company Builds Database for Material Test Reports 3
... 6, 2011 Spinal muscular atrophy (SMA) is the leading ... treatment other than supportive care. In the Proceedings of ... June 6), researchers at Children,s Hospital Boston show how loss ... and weakness, and suggest a promising approach to treating the ...
... 6, 2011 Oxford BioMedicaplc ("Oxford BioMedica" ... company, today announces that it has signed a research ... specialising in the development of engineered antibody fragments for ... in vivo diagnostic imaging agent using an ...
... Ganeden Biotech announced the sale of ... brands of probiotic dietary supplements to Schiff ...  Ganeden will also receive royalties on Schiff products containing ... rights to use Ganeden,s probiotic technology, GanedenBC30™, in the ...
Cached Biology Technology:New Approaches Open up in Spinal Muscular Atrophy 2New Approaches Open up in Spinal Muscular Atrophy 3Oxford BioMedica Announces 5T4 Antibody Research Collaboration with ImaginAb 2Oxford BioMedica Announces 5T4 Antibody Research Collaboration with ImaginAb 3Ganeden Biotech Completes $40 Million Sale of Sustenex® and Digestive Advantage® Probiotic Brands 2Ganeden Biotech Completes $40 Million Sale of Sustenex® and Digestive Advantage® Probiotic Brands 3
(Date:4/23/2014)... of Exeter researcher has shed light on how an ... Australia,s remote outback have become reviled as pests and ... the Environment and Sustainability Institute at the University of ... in Australia, from their historic role helping to create ... unwelcome "invader." , The deserts of the Australian outback ...
(Date:4/23/2014)... social mammals, ravens form different types of social relationships ... they also form strict dominance relations. From a cognitive ... key ability in daily social life ("knowing who is ... members have with each other sets the stage for ... of this study have been published in the scientific ...
(Date:4/23/2014)... a 2 million Food Standards Agency (FSA) project to ... industry workers. , Norovirus outbreaks can rapidly affect ... of frozen strawberries infected 11,000 people in Germany, but ... which strains cause infection and which foods are the ... Researchers will produce data that will help the FSA ...
Breaking Biology News(10 mins):How Australia got the hump with 1 million feral camels 2How Australia got the hump with 1 million feral camels 3Ravens understand the relations among others 2
... available in German . , A new ... could help to understand the positive effect of dietary restriction ... and mice) have shown that dietary restriction increases longevity, but ... the female fruit fly reproduces less frequently with a reduced ...
... discovery is challenging accepted thinking about amyloids the fibrous ... and may open up a potential new area for ... structures made up of proteins sometimes known as fibres - ... their formation which can damage cells and cause disease. ...
... Hausen and his co-workers discovered that specific types of human ... these pathogens cause cells to degenerate. It is known today ... Both proteins switch off different cellular control functions, thus promoting ... co-workers at DKFZ have now discovered another mechanism by which ...
Cached Biology News:How nutrition affects healthy aging 2New therapy targets for amyloid disease 2Papillomavirus silences innate immune response 2
... the Quansys Biosciences Q-Plex Array is a ... for human, mouse, and rat research. The ... quantitative ELISA-based test where 4 distinct capture ... of a 96-well plate in a defined ...
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
... kit for 10 chips provides the chips ... with the Experion automated electrophoresis system. This ... x 520 microliters Pro260 gel, 45 microliters ... kD), 400 microliters Pro260 sample buffer, and ...
... The expertise that made the original Gene ... electroporation system available has been applied in the ... circuitry. The modular design of the Gene Pulser ... the accessory that has the widest range of ...
Biology Products: